E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Patients having a knee arthrosis and undergoing a total knee prothesis surgery |
|
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 12.0 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10050155 |
E.1.2 | Term | Knee prosthesis insertion |
|
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 12.0 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10048794 |
E.1.2 | Term | Gonarthrosis |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
Study the impact of a biological glue administration on the bleeding loss during a total knee prosthesis surgery operation |
|
E.2.2 | Secondary objectives of the trial |
Study the impact of of a biological glue administration on : - the rate of cell saver transfusion the surgery day (J0) - the rate of red blood cell transfusion at J+1, J+3, J+5 and at the hospitalisation end - the hematomia size at J+1, J+3, J+5 and at the hospitalisation end - the site incision state at J+1, J+3, J+5 and at the hospitalisation end - the rest and mouvement pain at J+1, J+3, J+5 and at the hospitalisation end - the antalgic consumption at J+1, J+3, J+5 and at the hospitalisation end - the fonctional recovering index at J+1, J+3, J+5, at the hospitalisation end and at 1 month, 3 months and 6 months post-operative - the rate of major or clinicant significative hemorrhage between J+1 and the hospitalisation end - the rate ot thrombotics events between J+1 and the hospitalisation end - infectious complications between J+1 and the hospitalisation end - the rate of SUSARs between J+1 and the end of the study (6 months post-operative) |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
Patient affiliated with or a beneficiairy of a social security category: - having more than 18 years old - having signed the infomed consent form - having undergone a total knee prosthesis surgery operation
|
|
E.4 | Principal exclusion criteria |
- incapacity to understand the protocol - patient having taken anti-coagulants or clopidrogel 10 days before excepted aspirine to a dose equal or less than 160 mg/day - women having period so generaly women having less than 50 years old - PT less than 60% and ACT taller than 10 sec - contra-indications to the drug - Erytropoietine treatment required before surgery |
|
E.5 End points |
E.5.1 | Primary end point(s) |
- To evaluate the bleeding loss thanks to Gross formula: total blood volum x (hematocrit j-1 - hematocrit j+5) + red blood celle transfusion with total blood volum= weight x 70 for women and weight x 75 for men |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | No |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | Yes |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | Yes |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | Yes |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.3 |
The trial involves single site in the Member State concerned
| Yes |
E.8.4 | The trial involves multiple sites in the Member State concerned | No |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | Information not present in EudraCT |
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
| |
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 1 |
E.8.9.1 | In the Member State concerned months | 6 |
E.8.9.1 | In the Member State concerned days | |